title: Calreticulin as cancer treatment adjuvant: combination with photodynamic therapy and photodynamic therapy-generated vaccines.
abstract: Calreticulin is recognized as one of the pivotal damage-associated molecular pattern molecules alerting the host of the presence of distressed cells. In this role, calreticulin becomes exposed on the surface of tumor cells treated by several types of cancer therapy including photodynamic therapy (PDT). The goal of the present study was to examine the potential of externally added calreticulin for augmenting antitumor effect mediated by PDT. Recombinant calreticulin was found to bind to mouse SCCVII tumor cells treated by PDT. Compared to the outcome with PDT alone, cure rates of SCCVII tumors grown in immunocompetent C3H/HeN mice were elevated when calreticulin (0.4 mg/mouse) was injected peritumorally immediately after PDT. Such therapeutic gain with PDT plus calreticulin combination was not obtained with SCCVII tumors growing in immunodeficient NOD-scid mice. In PDT-vaccine protocol, where PDT-treated SCCVII cells are used for vaccination of SCCVII tumor-bearing mice, adding recombinant calreticulin to cells before their injection produced improved therapeutic effect. The expression of calreticulin gene was reduced in PDT-treated cells, while no changes were observed with the expression of this gene in tumor, liver, and spleen tissues in PDT-vaccine-treated mice. These findings reveal that externally added recombinant calreticulin can boost antitumor response elicited by PDT or PDT-generated vaccines, and can thus serve as an effective adjuvant for cancer treatment with PDT and probably other cancer cell stress-inducing modalities.
authors.affiliation: British Columbia Cancer Agency , Vancouver, BC , Canada.
authors.forename: Mladen
authors.initials: M
authors.lastname: Korbelik
authors.affiliation: British Columbia Cancer Agency , Vancouver, BC , Canada.
authors.forename: Judit
authors.initials: J
authors.lastname: Banáth
authors.affiliation: British Columbia Cancer Agency , Vancouver, BC , Canada.
authors.forename: Kyi Min
authors.initials: KM
authors.lastname: Saw
authors.affiliation: British Columbia Cancer Agency , Vancouver, BC , Canada.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Vilnius University Institute of Biotechnology , Vilnius , Lithuania.
authors.forename: Evaldas
authors.initials: E
authors.lastname: Čiplys
keywords: DAMPs; antitumor-immune response; calreticulin; cancer vaccine; photodynamic therapy